Haisco Pharmaceutical Group Co., Ltd.

Founded in 2000 and listed on the A-Share Market of Shenzhen Stock Exchange in Jan 2012, Haisco Pharmaceutical Group Co., Ltd (Haisco) is a specialized pharmaceutical group integrating new drugs development, manufacturing, and sales. As a high-tech enterprise, Haisco’s R&D capabilities ranks among the top in the chemical pharmaceutical industry in China. In 2025, Haisco achieved a revenue of RMB 4.387billion and a net profit of RMB 260million. Haisco owns a strong technical force. The R&D Center has over 1000 scientific researchers including experts with doctoral and master’s degree, Currently, about 50 projects are under development in R&D Center, involving multiple therapeutic areas such as anesthesia and analgesia, diabetes and associated complications, tumors, neuralgia, parenteral nutrition, cardiovascular, digestion and respiration, where 29 of them are First-Class new drugs. The self-developed new drug-Ciprofol, the first China’s brand-new intravenous anesthesia drug with independent intellectual property rights, was launched in China in 2020. At present, the four innovative drugs approved for marketing by the company are Ciprofol Injection, Crisugabalin Besilate Capsules, Cofrogliptin Tablets and Enrecofen Injection. certificatesThe R&D Center has its independent innovative drug research, generic drug research and pilot facilities, equipped with advanced precision research instruments, building an excellent experimental environment which is at a leading level in China. As of Dec. 31, 2025, aside of the projects under clinical and marketing stages, the Company has over 40 projects in the screening stage, involving therapeutic areas such as cancer, autoimmune system, respiratory system, and ophthalmology. At the same time, the Company continues to increase the R&D investments on the existing technology platforms, promoting drug discover and optimization, and driving the development, manufacturing, and commercialization of the new generation innovative drugs. At present, the Company has over 40 products on the market, most of them are the first or exclusive generic drug in China. The main products include Ciprofol Injection, Crisugabalin Besilate Capsules, Cofrogliptin Tabletsd and Enrecofen Injection. Haisco has a well-developed and mature sales channel. The Company has built a huge sales network covering major provinces and cities across the country based on the principle of "Self-Built Team, Cooperative Operation". Guided by the policy of "Medical Driven, Academic Leading, and Sales Implementation", a diversified marketing model and innovate pilot projects was adopted, transforming from point to area towards refinement, systematization, and platformization.